Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.
- Revenue up 285% to A$1.72 million, mainly interest income
- Net loss nearly doubled to A$23.4 million
- FDA confirms single pivotal Phase 3 trial design for ATH434 in MSA
- Strong cash position of A$37.3 million plus R&D tax incentive refund
- New US patent extends ATH434 protection to 2045
Financials Reflect Biotech Development Cycle
Alterity Therapeutics Limited (ASX:ATH) reported a significant increase in revenue for the year ended 30 June 2026, rising 285% to A$1.72 million. This was driven primarily by interest income on a larger cash balance, which stood at A$37.3 million at year-end, up from A$33.2 million in FY2025. However, the company also recorded a net loss after tax of A$23.4 million, up 92.6% from the prior year’s A$12.1 million, reflecting accelerating investment in its clinical development programs.
The company remains firmly in the development stage, focused on advancing its lead drug candidate ATH434, an iron chaperone designed to treat neurodegenerative diseases. No dividends were declared or paid, consistent with its ongoing investment phase.
FDA Alignment Clears Path for Pivotal Phase 3 Trial
The highlight of the year was the positive outcome of Alterity’s End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which confirmed agreement on the design of a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy (MSA). The trial will enrol around 200 patients, using the modified Unified MSA Rating Scale (UMSARS) Part I as the primary endpoint, and test a 50 mg twice daily dose of ATH434 over 12 months.
This regulatory clarity is a major milestone, providing a defined pathway for late-stage development and potential approval. The FDA’s acceptance of the 11-item UMSARS Part I as the primary endpoint is particularly encouraging, as it was the key clinical endpoint in the successful Phase 2 trial where ATH434 demonstrated a 46% relative treatment effect at week 52.
Preparations for the Phase 3 trial are well advanced, with manufacturing readiness confirmed by production of the first Good Manufacturing Practice (GMP) batch. Trial activities are expected to commence by the end of calendar 2026. The company also plans an open-label extension to continue treatment and bolster the safety database.
Strengthened Intellectual Property and Capital Position
In a boost to its commercial prospects, Alterity secured a new U.S. composition-of-matter patent covering a crystalline form of ATH434, extending intellectual property protection to 2045. This patent not only fortifies the MSA opportunity but also supports future development in Parkinson’s disease and other neurodegenerative indications.
Financially, Alterity ended FY2026 with a robust cash position of A$37.3 million, supplemented by a A$3.98 million research and development tax incentive refund received post-year-end. The company has actively engaged institutional investors in Australia and the U.S., and completed a one-for-fifty share consolidation in May 2026 to streamline its capital structure and enhance institutional appeal.
Risks and Outlook in a Competitive Landscape
Alterity’s fortunes remain closely tied to ATH434’s success. The company faces typical biotech risks including the need for substantial future funding, reliance on third-party manufacturing and clinical research institutions, and the inherent uncertainties of drug development and regulatory approval. Market acceptance and reimbursement remain open questions for any new therapeutic.
Competition in MSA is intensifying, with several other drug candidates in various stages of development, including monoclonal antibodies, receptor agonists, and gene therapies. Currently, no approved treatments modify the course of MSA, underscoring the unmet medical need.
Alterity’s management and board, including recently appointed independent director Ann Cunningham, are focused on executing the Phase 3 trial rigorously, managing capital prudently, and exploring strategic partnerships to maximise shareholder value.
Corporate and Governance Updates
Leadership changes in FY2026 included Julian Babarczy taking the chairmanship in November 2025 and David Stamler assuming the role of CEO and Managing Director. The company employs 11 staff split between Australia and the U.S., with a strong emphasis on research and development.
The financial statements were audited by PricewaterhouseCoopers with an unmodified opinion, and the audit highlighted the significant judgement involved in estimating the R&D tax incentive receivable of A$7.5 million.
Looking ahead, investors will be watching for the initiation of the Phase 3 trial, progress in manufacturing scale-up, and the company’s ability to secure additional funding or partnerships to support the costly late-stage development.
Bottom Line?
Alterity enters a critical phase with FDA-aligned Phase 3 plans and a strengthened patent estate, but funding needs and clinical risks remain pivotal.
Questions in the middle?
- Will Alterity secure sufficient funding to complete the Phase 3 trial and beyond?
- Can ATH434 replicate its Phase 2 efficacy in the larger, pivotal Phase 3 setting?
- How will the competitive landscape for MSA therapies evolve as other candidates progress?